Document is current
Any future updates will be listed below
-
Authors
Ibrahim, Kyrellos E.
Mears, Kepler S.
Allen, Peter M.
Chinai, Jordan M.
Avila, Omar I.
Muscato, Audrey J. https://orcid.org/0000-0003-2009-6313
Lane-Reticker, Sarah K.
Rojas, Alexander
Knudsen, Nelson H.
Chao, Chun-Cheih
Yates, Kathleen B.
Manguso, Robert T. https://orcid.org/0000-0003-1336-413X
-
Funding
Funding for this research was provided by:
Merkin Family Foundation Calico Life Science LLC
- License Information
-
More Information
Article History
Received: 29 April 2025
Accepted: 18 March 2026
First Online: 6 April 2026
Competing interests
: R.T.M., K.B.Y., K.S.M., K.E.I., and P.M.A. are inventors on patent applications filed by the Broad Institute relating to retargeted retroviral vector technologies and the use of morbillivirus-derived and VHH-targeted vectors described in this work (U.S. Patent Application Publications US 2024/0294942 A1 and US 2024/0307555 A1). R.T.M. has received speaking or consulting fees from Bristol Myers Squibb, Gilead Sciences, Kumquat Biosciences, Immunai Therapeutics, and BioNTech and has equity ownership in OncoRev, LLC, and Jumble Therapeutics. The remaining authors declare no competing interests.
